XEOMIN CHALLENGE

Xeomin is a purer form of botulinum toxin. Xeomin® was FDA-approved in 2011. Other types of FDA approved botulinum toxin includes Botox, Dysport and Jeuveau.

We are using Merz Aesthetics, the manufacturer of Xeomin, to give the aesthetic community the opportunity to try Xeomin at an introductory discount.

Most patients will see the full effect on days 3 – 7 and muscle relaxation may last up to 3 months. A clinical study that tested Xeomin versus other botulinum toxin in the frown lines concluded that Xeomin demonstrated a more rapid onset and a longer duration of treatment effect than other botulinum toxin. A different study looking at the crow’s feet concluded that Xeomin worked and lasted as long as other botulinum toxin.

Three areas around the eyes are the most commonly injected: frown lines, horizontal forehead lines, and crow’s feet. Other areas on the face may be injected depending on your injector's expertise.

The first area of injection includes an injection fee of $89 + $3/unit of Xeomin. You must activate XperienceMerz.com, which give you a discount of $50.  Therefore, 20 units of Xeomin is $149 minus $50 rewards credit, which equals $99.

Each additional area includes an injection fee of $39 + $3/unit of Xeomin.

20 UNITS = $99
10 UNITS = $69

Please click on the list of Park Medspa locations where you can participate in the Xeomin Challenge. 

Please click on the list of Park Medspa locations for a list of dates when you can participate in the Xeomin Challenge.  You can also use the form below to join our waitlist.

All Medical Professional injectors are physicians, nurse practitioners or physician assistants with extensive experience.

Park Medspa is offering this introductory offer to aesthetic influencers at an amazing price to try Xeomin for the first time. In order to qualify, you must not have had Xeomin in the past 90 days, pass medical screening questions and sign waiver and consent forms. 

There is no injection fee for any touch ups within 2 weeks of your initial visit. You are charged $3/unit for the touch up.

You are able to receive another Xeomin injection again.  However, we CANNOT guarantee that the offer of $99 per 20 units of Xeomin will be available at a future date.

Various symptoms such as asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties have been observed from hours to weeks following the injection.

There have been reports of death related to the spread of botulinum toxin from swallowing or breathing difficulties. You MUST seek immediate medical attention if swallowing, speech, or respiratory disorders occur.

Hypersensitivity reactions such as anaphylaxis, serum sickness, urticaria, soft-tissue edema, and dyspnea have been reported. Any hypersensitivity to neurotoxin, human albumin, or sucrose can lead to life threatening anaphylaxis. If you experience any of the symptoms, then immediate medical attention is required.

Corneal exposure, ulceration, or ectropion has been reported. The loss of orbicularis muscle can lead to complications.

Xeomin also contains albumin, which is a derivative of human blood. Therefore, there is a theoretical risk of viral diseases, CJD, or vCJD, although none has ever been reported.

Xeomin is contraindicated in the following patients with known hypersensitivity to botulinum toxin or other components in the formulation or an infection at the site of injection.

Patients with peripheral motor neuropathy diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) are at increased risk and cannot be injected.

Please visit: https://ParkMedspa.com/info/

This has the links to fill out your medical history forms, consent forms, and to sign up for Xperience+ Rewards with Merz ahead of your appointment.

Please contact us at:
(619) 313-0495 for SD
(714) 391-5064 for OC
email@ParkMedspa.com

Or try our Facebook Messenger Chat on the bottom right corner of this webpage.